MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

INKT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

MiNK Therapeutics, Inc.NASDAQ: INKT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 4.8M shares rose 21.0% year over year, ahead of the +13.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.0% holds above the trailing-twelve-month pace of +13.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
4.8M+12.4% QoQ
Last fiscal yearDec 2025
4.27M+10.5% YoY
LTMMar 2026
4.37M+13.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.0%——
1 year+10.5%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
4.27M USD
Year-over-year change
+10.5%
4-year CAGR
+6.3%

Weighted Avg Shares (Diluted) vs competitors

How INKT compares with its peers on the latest reported figures

  • INKT's LTM Mar 2026 weighted avg shares (diluted) of 4.37M shares is the 8th highest of the 9 companies compared; the peer median is 29.8M shares.
  • Its year-over-year change of +13.5% is the 7th highest of 9, against a peer median of +34.2%.
  • Over three fiscal years its annual growth of +8.2% compares with a peer median of +25.7%.
INKT Competitors Peer median
Weighted Avg Shares (Diluted) for INKT and competitors
Company Period LTM YoY 3-year CAGR
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
HOWLWerewolf Therapeutics, Inc.LTM Jun 202647.65M +7.1%+17.5%
GANXGain Therapeutics, Inc.LTM Mar 202635.13M +38.4%+40.5%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
VTVTvTv Therapeutics Inc.LTM Mar 20267.87M +30.1%+63.7%
INKTMiNK Therapeutics, Inc.LTM Mar 20264.37M +13.5%+8.2%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding INKT) 29.8M+34.2%+25.7%

Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue77.96K121.75K204.62K215.44K181.75K
Gross Profit(77.96K)(121.75K)(204.62K)(215.44K)(181.75K)
Gross Margin—————
Research & Development13.97M23.12M15.49M6.34M5.76B
Selling, General & Admin4.56M7.71M7.43M4.1M6.73B
Operating Expenses18.53M30.83M22.72M10.43M12.31M
Depreciation & Amortization77.96K121.75K204.62K215.44K181.75K
EBITDA(27.7M)(27.87M)(22.25M)(10.57M)(12.31M)
EBITDA Margin—————
Operating Income(18.61M)(30.95M)(22.92M)(10.65M)(12.49M)
Operating Margin—————
Interest Income2.43K253.32K463.26K172.57K180.25K
Interest Expense2.43M253.32K000
Other Income / Expenses(11.61M)2.96M463.25K(134.56K)(6.96K)
Income Before Tax(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Net Margin—————
EPS (Basic)(9.03)(8.31)(6.54)(2.90)(2.93)
EPS (Diluted)(9.03)(8.31)(6.54)(2.80)(2.93)
Weighted Avg Shares3.35M3.37M3.44M3.74M4.27M
Weighted Avg Shares (Diluted)3.35M3.37M3.44M3.86M4.27M

MiNK Therapeutics, Inc.

NASDAQ:INKT

Intrinsic Alpha fair value

Locked

Current Price

$10.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.